Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Venetoclax for AML: changing the treatment paradigm
Daniel A. Pollyea, Maria L. Amaya, Paolo Strati, et al.
Blood Advances (2019) Vol. 3, Iss. 24, pp. 4326-4335
Open Access | Times Cited: 143

Showing 1-25 of 143 citing articles:

Advances in acute myeloid leukemia
Laura F. Newell, Rachel J. Cook
BMJ (2021), pp. n2026-n2026
Open Access | Times Cited: 304
Recent Advances in Oligonucleotide Therapeutics in Oncology
Haoyu Xiong, Rakesh N. Veedu, Sarah D. Diermeier
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 7, pp. 3295-3295
Open Access | Times Cited: 148
Immunotherapy in Acute Myeloid Leukemia: Where We Stand
Alessandro Isidori, Claudio Cerchione, Naval Daver, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 84
New strategies to treat AML: novel insights into AML survival pathways and combination therapies
Ramya Nair, Alejandro Salinas-Illarena, Hanna‐Mari Baldauf
Leukemia (2020) Vol. 35, Iss. 2, pp. 299-311
Closed Access | Times Cited: 71
Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progression
Lindsay Stetson, Dheepa Balasubramanian, Susan Pereira Ribeiro, et al.
Leukemia (2021) Vol. 35, Iss. 10, pp. 2799-2812
Open Access | Times Cited: 65
Menin Inhibitors in Acute Myeloid Leukemia—What Does the Future Hold?
Mahesh Swaminathan, Wallace Bourgeois, Scott A. Armstrong, et al.
The Cancer Journal (2022) Vol. 28, Iss. 1, pp. 62-66
Closed Access | Times Cited: 40
Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Christina Glytsou, Xufeng Chen, Emmanouil Zacharioudakis, et al.
Cancer Discovery (2023) Vol. 13, Iss. 7, pp. 1656-1677
Open Access | Times Cited: 29
Uncovering expression signatures of synergistic drug responses via ensembles of explainable machine-learning models
Joseph D. Janizek, Ayse B. Dincer, Safiye Çelik, et al.
Nature Biomedical Engineering (2023) Vol. 7, Iss. 6, pp. 811-829
Closed Access | Times Cited: 28
The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways
Maryam Bakhtiyari, Mahsa Liaghat, Fatemeh Aziziyan, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 25
AVALON: The Italian cohort study on real‐life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia
Elisabetta Todisco, Cristina Papayannidis, Nicola Fracchiolla, et al.
Cancer (2023) Vol. 129, Iss. 7, pp. 992-1004
Open Access | Times Cited: 24
Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2
Yunhang Guo, Hai Xue, N. X. HU, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 10, pp. 7836-7858
Open Access | Times Cited: 8
Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia
Zhiyu Zhang, Jiayi Huang, Zhibo Zhang, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 8
How I diagnose and treat NPM1-mutated AML
Brunangelo Falini, Lorenzo Brunetti, Maria Paola Martelli
Blood (2020) Vol. 137, Iss. 5, pp. 589-599
Open Access | Times Cited: 58
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine
Nora E. Rahmani, Nandini Ramachandra, Srabani Sahu, et al.
Blood Cancer Journal (2021) Vol. 11, Iss. 9
Open Access | Times Cited: 46
CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues
Xiaobing Yu, Leonel Muñoz‐Sagredo, Karolin Streule, et al.
Blood (2021) Vol. 138, Iss. 12, pp. 1067-1080
Open Access | Times Cited: 41
Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets
Sushanta Kumar Mishra, Scott E. Millman, Lingbo Zhang
Blood (2022) Vol. 141, Iss. 10, pp. 1119-1135
Open Access | Times Cited: 32
Biomarkers as targets for CAR-T/NK cell therapy in AML
Ruonan Shao, Zijian Li, Hong-Lei Xin, et al.
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 21
Updates on Drug Designing Approach Through Computational Strategies: a Review
Iqbal Azad, Tahmeena Khan, Naseem Ahmad, et al.
Future Science OA (2023) Vol. 9, Iss. 5
Open Access | Times Cited: 20
Venetoclax with Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Survival Data from Real-World Studies
Andrealuna Ucciero, F Pagnoni, Lorenza Scotti, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4618-4618
Open Access | Times Cited: 19
ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia
Jessica Ebner, Johannes Schmoellerl, Martin Piontek, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 18
Cheminformatics-Based Study Identifies Potential Ebola VP40 Inhibitors
Emmanuel Broni, Carolyn Ashley, Joseph Adams, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6298-6298
Open Access | Times Cited: 16
Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors
Helen T. Chifotides, Lucia Masárová, Mansour Alfayez, et al.
Blood Advances (2020) Vol. 4, Iss. 21, pp. 5336-5342
Open Access | Times Cited: 45
Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine
Ralf Buettner, Le Xuan Truong Nguyen, Corey Morales, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 40
The application of BH3 mimetics in myeloid leukemias
Narissa Parry, Helen Wheadon, Mhairi Copland
Cell Death and Disease (2021) Vol. 12, Iss. 2
Open Access | Times Cited: 38
Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies
Jonathan Feld, Douglas Tremblay, Mikaela Dougherty, et al.
HemaSphere (2021) Vol. 5, Iss. 4, pp. e549-e549
Open Access | Times Cited: 37
Page 1 - Next Page

Scroll to top